The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System

Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Na Zhang [verfasserIn] Yanan Huo [verfasserIn] Chen Yao [verfasserIn] Jie Sun [verfasserIn] Yafeng Zhang [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Übergeordnetes Werk:	In: Journal of the Renin-Angiotensin-Aldosterone System - SAGE Publications, 2014, (2022)
Übergeordnetes Werk:	year:2022

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.1155/2022/9067167

Katalog-ID:	DOAJ098538144

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ098538144
003	DE-627
005	20240413230828.0
007	cr uuu---uuuuu
008	240413s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1155/2022/9067167 \|2 doi
035			\|a (DE-627)DOAJ098538144
035			\|a (DE-599)DOAJ48be0313e19c47048dd09d581d631b60
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R5-920
100	0		\|a Na Zhang \|e verfasserin \|4 aut
245	1	4	\|a The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration.
653		0	\|a Medicine (General)
700	0		\|a Yanan Huo \|e verfasserin \|4 aut
700	0		\|a Chen Yao \|e verfasserin \|4 aut
700	0		\|a Jie Sun \|e verfasserin \|4 aut
700	0		\|a Yafeng Zhang \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of the Renin-Angiotensin-Aldosterone System \|d SAGE Publications, 2014 \|g (2022) \|w (DE-627)52147485X \|w (DE-600)2261873-9 \|x 17528976 \|7 nnns
773	1	8	\|g year:2022
856	4	0	\|u https://doi.org/10.1155/2022/9067167 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/48be0313e19c47048dd09d581d631b60 \|z kostenfrei
856	4	0	\|u https://doi.org/10.1155/2022/9067167 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1470-3203 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1752-8976 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_374
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2022

Indexfelder

author_variant	n z nz y h yh c y cy j s js y z yz
matchkey_str	article:17528976:2022----::hefcotenitnicnetnezmihbtrnoeelhnataehpresvrtim
hierarchy_sort_str	2022
callnumber-subject-code	R
publishDate	2022
allfields	10.1155/2022/9067167 doi (DE-627)DOAJ098538144 (DE-599)DOAJ48be0313e19c47048dd09d581d631b60 DE-627 ger DE-627 rakwb eng R5-920 Na Zhang verfasserin aut The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration. Medicine (General) Yanan Huo verfasserin aut Chen Yao verfasserin aut Jie Sun verfasserin aut Yafeng Zhang verfasserin aut In Journal of the Renin-Angiotensin-Aldosterone System SAGE Publications, 2014 (2022) (DE-627)52147485X (DE-600)2261873-9 17528976 nnns year:2022 https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/article/48be0313e19c47048dd09d581d631b60 kostenfrei https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/toc/1470-3203 Journal toc kostenfrei https://doaj.org/toc/1752-8976 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022
spelling	10.1155/2022/9067167 doi (DE-627)DOAJ098538144 (DE-599)DOAJ48be0313e19c47048dd09d581d631b60 DE-627 ger DE-627 rakwb eng R5-920 Na Zhang verfasserin aut The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration. Medicine (General) Yanan Huo verfasserin aut Chen Yao verfasserin aut Jie Sun verfasserin aut Yafeng Zhang verfasserin aut In Journal of the Renin-Angiotensin-Aldosterone System SAGE Publications, 2014 (2022) (DE-627)52147485X (DE-600)2261873-9 17528976 nnns year:2022 https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/article/48be0313e19c47048dd09d581d631b60 kostenfrei https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/toc/1470-3203 Journal toc kostenfrei https://doaj.org/toc/1752-8976 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022
allfields_unstemmed	10.1155/2022/9067167 doi (DE-627)DOAJ098538144 (DE-599)DOAJ48be0313e19c47048dd09d581d631b60 DE-627 ger DE-627 rakwb eng R5-920 Na Zhang verfasserin aut The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration. Medicine (General) Yanan Huo verfasserin aut Chen Yao verfasserin aut Jie Sun verfasserin aut Yafeng Zhang verfasserin aut In Journal of the Renin-Angiotensin-Aldosterone System SAGE Publications, 2014 (2022) (DE-627)52147485X (DE-600)2261873-9 17528976 nnns year:2022 https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/article/48be0313e19c47048dd09d581d631b60 kostenfrei https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/toc/1470-3203 Journal toc kostenfrei https://doaj.org/toc/1752-8976 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022
allfieldsGer	10.1155/2022/9067167 doi (DE-627)DOAJ098538144 (DE-599)DOAJ48be0313e19c47048dd09d581d631b60 DE-627 ger DE-627 rakwb eng R5-920 Na Zhang verfasserin aut The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration. Medicine (General) Yanan Huo verfasserin aut Chen Yao verfasserin aut Jie Sun verfasserin aut Yafeng Zhang verfasserin aut In Journal of the Renin-Angiotensin-Aldosterone System SAGE Publications, 2014 (2022) (DE-627)52147485X (DE-600)2261873-9 17528976 nnns year:2022 https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/article/48be0313e19c47048dd09d581d631b60 kostenfrei https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/toc/1470-3203 Journal toc kostenfrei https://doaj.org/toc/1752-8976 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022
allfieldsSound	10.1155/2022/9067167 doi (DE-627)DOAJ098538144 (DE-599)DOAJ48be0313e19c47048dd09d581d631b60 DE-627 ger DE-627 rakwb eng R5-920 Na Zhang verfasserin aut The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration. Medicine (General) Yanan Huo verfasserin aut Chen Yao verfasserin aut Jie Sun verfasserin aut Yafeng Zhang verfasserin aut In Journal of the Renin-Angiotensin-Aldosterone System SAGE Publications, 2014 (2022) (DE-627)52147485X (DE-600)2261873-9 17528976 nnns year:2022 https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/article/48be0313e19c47048dd09d581d631b60 kostenfrei https://doi.org/10.1155/2022/9067167 kostenfrei https://doaj.org/toc/1470-3203 Journal toc kostenfrei https://doaj.org/toc/1752-8976 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2022
language	English
source	In Journal of the Renin-Angiotensin-Aldosterone System (2022) year:2022
sourceStr	In Journal of the Renin-Angiotensin-Aldosterone System (2022) year:2022
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Medicine (General)
isfreeaccess_bool	true
container_title	Journal of the Renin-Angiotensin-Aldosterone System
authorswithroles_txt_mv	Na Zhang @@aut@@ Yanan Huo @@aut@@ Chen Yao @@aut@@ Jie Sun @@aut@@ Yafeng Zhang @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	52147485X
id	DOAJ098538144
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098538144</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413230828.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1155/2022/9067167</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098538144</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ48be0313e19c47048dd09d581d631b60</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Na Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yanan Huo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen Yao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jie Sun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yafeng Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of the Renin-Angiotensin-Aldosterone System</subfield><subfield code="d">SAGE Publications, 2014</subfield><subfield code="g">(2022)</subfield><subfield code="w">(DE-627)52147485X</subfield><subfield code="w">(DE-600)2261873-9</subfield><subfield code="x">17528976</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2022</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1155/2022/9067167</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/48be0313e19c47048dd09d581d631b60</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1155/2022/9067167</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1470-3203</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1752-8976</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2022</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Na Zhang
spellingShingle	Na Zhang misc R5-920 misc Medicine (General) The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System
authorStr	Na Zhang
ppnlink_with_tag_str_mv	@@773@@(DE-627)52147485X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	17528976
topic_title	R5-920 The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System
topic	misc R5-920 misc Medicine (General)
topic_unstemmed	misc R5-920 misc Medicine (General)
topic_browse	misc R5-920 misc Medicine (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of the Renin-Angiotensin-Aldosterone System
hierarchy_parent_id	52147485X
hierarchy_top_title	Journal of the Renin-Angiotensin-Aldosterone System
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)52147485X (DE-600)2261873-9
title	The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System
ctrlnum	(DE-627)DOAJ098538144 (DE-599)DOAJ48be0313e19c47048dd09d581d631b60
title_full	The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System
author_sort	Na Zhang
journal	Journal of the Renin-Angiotensin-Aldosterone System
journalStr	Journal of the Renin-Angiotensin-Aldosterone System
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
author_browse	Na Zhang Yanan Huo Chen Yao Jie Sun Yafeng Zhang
class	R5-920
format_se	Elektronische Aufsätze
author-letter	Na Zhang
doi_str_mv	10.1155/2022/9067167
author2-role	verfasserin
title_sort	effect of the angiotensin-converting enzyme inhibitor on bone health in castrated hypertensive rats is mediated via the kinin-kallikrein system
callnumber	R5-920
title_auth	The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System
abstract	Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration.
abstractGer	Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration.
abstract_unstemmed	Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_374 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System
url	https://doi.org/10.1155/2022/9067167 https://doaj.org/article/48be0313e19c47048dd09d581d631b60 https://doaj.org/toc/1470-3203 https://doaj.org/toc/1752-8976
remote_bool	true
author2	Yanan Huo Chen Yao Jie Sun Yafeng Zhang
author2Str	Yanan Huo Chen Yao Jie Sun Yafeng Zhang
ppnlink	52147485X
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1155/2022/9067167
callnumber-a	R5-920
up_date	2024-07-03T17:49:41.100Z
_version_	1803581108893253632
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ098538144</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413230828.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1155/2022/9067167</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ098538144</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ48be0313e19c47048dd09d581d631b60</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Na Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background . In previous studies, angiotensin-converting enzyme inhibitor (ACEI) use was associated with increased bone loss, while an angiotensin II type I receptor blocker had no effect on bone loss in elder subjects, which suggested that the effect of ACEI on bone loss was not mediated through the classical renin-angiotensin system. In this study, we set to investigate whether the effect of ACEI on bone deterioration was mediated via the kinin-kallikrein system. Methods . Six-month-old male and female spontaneously hypertensive rats were used. The effect of captopril on blood pressure, serum Ang II, and bradykinin concentration was measured in intact rats. Ovariectomy and orchidectomy were performed to establish an osteoporosis model in female and male rats, respectively. Captopril and the bradykinin receptor blocker icatibant (HOE140) were administered after operation for 12 weeks. Serum Ang II and bradykinin concentration, bone turnover markers, bone mineral density (BMD), and bone microarchitecture were evaluated. Femur samples were subjected to a mechanical test. Results . Captopril decreased blood pressure and serum Ang II concentration and increased serum bradykinin concentration in intact rats ( P < 0.05 ). After castration, captopril decreased serum Ang II concentration ( P < 0.05 ); in female rats, icatibant increased serum Ang II concentration ( P < 0.05 ). Captopril increased serum bradykinin concentration ( P < 0.05 ); in male rats, icatibant decreased serum bradykinin concentration ( P < 0.05 ). Captopril increased the rat urine deoxypyridinoline-creatinine ratio (DPD/Cr) and serum osteocalcin concentration ( P < 0.05 ). Icatibant decreased urine DPD/Cr in male rats ( P < 0.05 ) and increased osteocalcin concentration in female rats ( P < 0.05 ). Captopril increased cancellous BMD in castrated hypertensive rats ( P < 0.05 ), and icatibant further increased cancellous BMD ( P < 0.05 ), which was due to the increased trabecular bone number. In mechanical testing, ACEI increased bone strength ( P < 0.05 ), and icatibant further improved it ( P < 0.05 ). Conclusion . ACEI decreased bone deterioration in both male and female hypertensive rats, and the bradykinin receptor blocker further decreased bone deterioration.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yanan Huo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen Yao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jie Sun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yafeng Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of the Renin-Angiotensin-Aldosterone System</subfield><subfield code="d">SAGE Publications, 2014</subfield><subfield code="g">(2022)</subfield><subfield code="w">(DE-627)52147485X</subfield><subfield code="w">(DE-600)2261873-9</subfield><subfield code="x">17528976</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2022</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1155/2022/9067167</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/48be0313e19c47048dd09d581d631b60</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1155/2022/9067167</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1470-3203</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1752-8976</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2022</subfield></datafield></record></collection>
score	7.4010754

Nicht das Richtige dabei?

Schreiben Sie uns!

The Effect of the Angiotensin-Converting Enzyme Inhibitor on Bone Health in Castrated Hypertensive Rats Is Mediated via the Kinin-Kallikrein System

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?